CAS 242478-38-2|solifenacin succinate

Introduction：Basic information about CAS 242478-38-2|solifenacin succinate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. solifenacin succinate BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	solifenacin succinate
CAS Number	242478-38-2	Molecular Weight	480.553
Density	1.24g/cm3	Boiling Point	505.5ºC at 760 mmHg
Molecular Formula	C₂₇H₃₂N₂O₆	Melting Point	147 °C
MSDS	/	Flash Point	259.5ºC

Names

Name	Solifenacin succinate
Synonym	More Synonyms

solifenacin succinate BiologicalActivity

Description	Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.IC50 value:Target: muscarinic receptorSolifenacin succinate (YM905; Vesicare) is a prescription medication used to treat certain bladder problems.
Related Catalog	Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease
References	[1]. Krishna SR, Rao BM, Rao NS.A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.J Chromatogr Sci. 2010 Nov;48(10):807-10. [2]. Ohtake A, Sato S, Sasamata M, Miyata K.The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4. [3]. Hoffstetter S, Leong FC.Solifenacin succinate for the treatment of overactive bladder.Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50. [4]. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Int J Clin Pract. 2008 Nov;62(11):1675-83. [5]. Imamura T, et al.Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033.

Description

Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.IC50 value:Target: muscarinic receptorSolifenacin succinate (YM905; Vesicare) is a prescription medication used to treat certain bladder problems.

Related Catalog

Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease

References

[1]. Krishna SR, Rao BM, Rao NS.A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.J Chromatogr Sci. 2010 Nov;48(10):807-10.

[2]. Ohtake A, Sato S, Sasamata M, Miyata K.The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4.

[3]. Hoffstetter S, Leong FC.Solifenacin succinate for the treatment of overactive bladder.Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50.

[4]. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Int J Clin Pract. 2008 Nov;62(11):1675-83.

[5]. Imamura T, et al.Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033.

Chemical & Physical Properties

Density	1.24g/cm3
Boiling Point	505.5ºC at 760 mmHg
Melting Point	147 °C
Molecular Formula	C₂₇H₃₂N₂O₆
Molecular Weight	480.553
Flash Point	259.5ºC
Exact Mass	480.226044
PSA	107.38000
LogP	3.67650
Vapour Pressure	2.41E-10mmHg at 25°C
Index of Refraction	1.648
InChIKey	RXZMMZZRUPYENV-VROPFNGYSA-N
SMILES	O=C(O)CCC(=O)O.O=C(OC1CN2CCC1CC2)N1CCc2ccccc2C1c1ccccc1

Safety Information

Hazard Codes	Xi

Synonyms

1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid

(1R,3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate

(3R)-1-Azabicyclo[2.2.2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate butanedioate

2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)-, butanedioate (1:1)

Succinic acid - (3R)-1-azabicyclo[2.2.2]oct-3-yl (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate (1:1)

solifenacin succinate

Vesikur

Solifenacin succinate [USAN]

T66 CNT&J BR& CVO- AT66 A B CNTJ &&(1S)-(3R)- Form succinate

Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)

IsoprenalinoeSulfate

(1S)-(3R)-1-Azabicyclo[2.2.2]oct-3-yl 3,4-Dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate Butanedioic Acid

Vesicare

Solifenacin (Succinate)

Recommended......